Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

PharmaJet and Immuno Cure partner to advance needle-free HIV therapeutic DNA vaccine

Closely held PharmaJet announced that it has signed an agreement with closely held Immuno Cure, a developer of DNA vaccines. Under the agreement, Immuno Cure will use PharmaJet’s Tropis Intradermal (ID) Needle-Free...

June 19, 2025

Executive Moves

Retina specialist Dr. Lloyd Clark joins Annexon

Annexon (NASDAQ: ANNX) announced the appointment of Lloyd Clark, MD, as SVP, ophthalmology strategy and innovation. Dr. Clark brings more than 25 years of experience in treating retinal diseases and advancing novel...

June 19, 2025

Developments

Transgene advances TG4050 to Phase 2 in head and neck cancer trial

Transgene (Euronext Paris: TNG) announced the completion of initial patient screening in the Phase 2 portion of its ongoing Phase 1/2 clinical trial of TG4050—an individualized neoantigen therapeutic...

June 19, 2025

Developments

Telomir’s lead candidate prevents cellular aging in patient-derived cells from children with Progeria

Telomir Pharmaceuticals (NASDAQ: TELO) announced new preclinical data showing that Telomir-1 prevented cellular aging in patient-derived cells from children with progeria—Hutchinson-Gilford Progeria Syndrome (HGPS)—an...

June 18, 2025

Executive Moves

Avalo appoints Dr. Rita Jain to BOD

Avalo Therapeutics (NASDAQ: AVTX) has announced the appointment of Rita Jain, MD, to its board of directors (BOD). To this role, Dr. Jain, a rheumatologist, brings more than two decades of leadership in...

June 18, 2025

Developments

MAIA enters into agreement with Roche to investigate THIO with Tecentriq

MAIA Biotechnology (NYSE American: MAIA) announced it has entered into a master supply agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to investigate the combination of MAIA’s telomere-targeting agent ateganosine...

June 18, 2025

Developments

Ekso Bionics’ Acceptance into NVIDIA Connect Program Bears Early Fruit

Ekso Bionics Holdings (NASDAQ:EKSO) has announced that it has successfully demonstrated initial proof-of-concept in integrating new AI-enabled capabilities across its portfolio of Enterprise Health and Personal Health...

June 18, 2025

Developments

USPTO issues patent for Lipella’s diagnostic technology

Lipella Pharmaceuticals (NASDAQ: LIPO) announced that on June 10, 2025 the U.S. Patent and Trademark Office (USPTO) issued Patent No. 12,326,492, titled Systems and Methods of Detecting Interstitial Cystitis, providing...

June 17, 2025

Developments

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Cellectar Biosciences (NASDAQ: CLRB) announced initial results as of June 10, 2025, from its CLOVER-2 Phase 1 trial evaluating iopoffosine I 131 in relapsed/refractory pediatric high-grade glioma (pHGG) patients...

June 11, 2025

Developments

Adial’s lead AUD candidate advances toward Phase 3 trial

Adial Pharmaceuticals (NASDAQ: ADIL) announced that its lead investigational candidate—AD04—a therapeutic agent for alcohol use disorder (AUD) is progressing toward a Phase 3 trial. According to Adial, as part of its...

June 11, 2025

Executive Moves

Beacon appoints Dr. Daniel Chung as CMO

Closely held Beacon Therapeutics announced the appointment of Dr. Daniel Chung as chief medical officer (CMO), effective immediately. Dr. Chung brings more than three decades of experience in ophthalmology, academic...

June 11, 2025

Executive Moves

Laura Conquergood joins Baylis as CEO

Closely held Baylis Medical Technologies announced the appointment of Laura Conquergood as chief executive officer (CEO). Kris Shah, formerly president and CEO, and Frank Baylis, formerly executive chairman, have both...

June 11, 2025

Subscribe